Review Article
Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer
Table 4
Some examples of PEG-modified PLGA NPs with preparation methods, targeting ligands, size, zeta potential, and applications.
| Polymer | Targeting ligand | Conjugation method | Average size (nm) | Zeta potential (mV) | Applications | Reference |
| PEGylated PLGA | A10 aptamer | Covalent conjugation | 188 | N/A | Targeting human xenograft prostate cancer in mice | [93] |
| PLGA-PEG | — | Covalent conjugation | 170 | N/A | NPs encapsulating endostar slowed growth of tumor xenografts | [94] |
| PEGylated PLGA | cLABL | Covalent conjugation | 244 | −23.3 | Targeting the vascular endothelium with upregulated ICAM-1 | [95] |
| 50/50 PLGA and Palmitate-Avidin | Biotinylated PEG, and horseradish peroxidase | Streptavidin-biotin noncovalent binding | 170 | −11.3 | Diffusion of PEGylated particles cervical mucus was 3–10x higher than unmodified PLGA | [96] |
| PLGA-PEG | — | Covalent conjugation | 148 | 1.84 | Sustained release of 9-nitrocamptothecin | [97] |
| PLGA-PEG | | Covalent conjugation | 65–100 | N/A | Sustained release of adriamycin | [98] |
| PLA-PEG | | Covalent conjugation | 952 | Neutral | Reduced opsonization of NPs | [99] |
| PLGA and PEG-distearyl Phosphoethanolamine (PEGPE) | | Coemulsification | 20–40 | −19.2 | Higher Doxorubicin encapsulation efficiency, slower release rate, and rapid cellular uptake | [100] |
| PLGA-mPEG | | Covalent conjugation | N/A | N/A | Reduction in protein adsorption on the surface films of PLGA-PEG (750 and 2000) compared to adsorption onto PLGA only | [101] |
| PLGA | PEG/poloxamer 407 | Coincorporation or surface adsorption | 189–225 | (−16.1)–(−20.3) | Increased blood circulation half-life of NPs | [102] |
| PLGA-PEG di-block (15% PEG with 5 kDa) | | Covalent conjugation | 114 | −2.8 | Higher cellular uptake of formulations containing 15% of PEG compared to 5% and 10% PEG-PLGA formulations | [103] |
|
|